Veropharm

Aktivs

In 2016, Veropharm includes:

• Voronezh Chemical and Pharmaceutical Plant,
• plant in the village of Volginsky, Vladimir region,
• Belgorod enterprise for the manufacture of finished dosage forms and
• Pokrovsky plant of finished dosage forms.

These enterprises have a total production capacity of 591 million tablets and capsules, 7 million ampoules, 468 million patches and 43 million vials annually. The company produces more than 300 products.

By the end of 2016, it is planned to launch commercial production at a new plant in the village of Volginsky, Vladimir Region.

Plant in Belgorod

In 2016, the Belgorod Veropharma plant produces over 100 drugs used in oncology, hepatology, neurology, gastroenterology, gynecology, as well as vitamins. Among the Abbott drugs in Belgorod, the production of Dufalac, Duspatalin and Dufaston is localized. The company employs more than 600 employees.

Performance indicators

According to SPARK-Interfax, in 2015, JSC's revenue amounted to 3.3 billion rubles, net profit - 17.7 million rubles.

History

2024: Appointment of Maria Zazulevskaya as CEO

In January 2024, Maria Zazulevskaya became the new CEO of Veropharm. She replaced Ivan Polyak, who headed the manufacturer of drugs since 2019. He was also Senior Director for Commercial Development, Strategy and Sales of Abbott's drug division at the company's head office. Read more here.

2021: The opening of the Scientific and Technical Production Center in conjunction with Abbott

On October 19, 2021, Abbott announced the opening of the Scientific and Technical Production Center at the Veropharm production site (Abbott Group) in Belgorod. The center will speed up the process of transferring production technologies, localizing the company's international portfolio, as well as developing and releasing high-quality medicines on the Russian market. The launch of the Center was attended by the First Deputy Minister of Industry and Trade of the RFVasiliy Osmakov and the Governor of the Belgorod Region Vyacheslav Gladkov.

We are launching an updated program for the development of pharmaceutical the industry - "Pharma 2030." Her basic message is that we have exhausted the pharma industry growth model, which is based on straightforward import substitution and generic. That is why R&D Russian companies, foreign companies, in particular, this Scientific and Technical Production Center of Abbott is an important step in the strategic direction, which fully corresponds to the priorities of Pharma 2030. It is very important that the center opens on a site that produces socially significant drugs, in particular, for. cancer therapy The very discovery indicates that the industry model, which is based both on Russian developments and on the effective transfer of foreign companies, is viable, "said First Deputy Minister industries and Vasily trade RUSSIAN FEDERATION Osmakov.

The transfer of production technologies is one of the main tasks of the Scientific and Technical Production Center, where engineering and validation batches will be produced, as well as batches for subsequent clinical trials. All production processes are carried out on current equipment and will be scaled into mass production in accordance with GMP standards at the Veropharm production complex (Abbott group) in Belgorod.

In the field of pharmaceutical production, Abbott pays equal attention in Russia to two areas: ensuring the availability of local drugs "Veropharm" (Abbott Group), which are socially significant for healthcare, among which popular drugs for the treatment of cancer, as well as the localization of international Abbott drugs carried out through the transfer of technologies, - said Sammi Karam, Senior Vice President of the Abbott Drug Division. - For 5 years, Abbott has invested $210 million in modernizing the pharmaceutical production of Veropharm (Abbott Group) in Russia. Investments in the creation of the Scientific and Technical Production Center amounted to $4 million (300 million rubles).

The opening of this Scientific and Technical Production Center in Russia meets Abbott's global goal of increasing the availability of high-quality therapy. The center operates on the basis of Veropharm (Abbott group) in Belgorod - a platform with a large portfolio of socially significant products in the field of oncology, cardiology, neurology, gastroenterology and female reproductive health.

2019: Launch of two additional production lines at a plant in the village of Volginsky

On October 11, 2019, it became known that the general director of Veropharm and the governor of the Vladimir region announced the launch of two additional production lines for sterile injectable drugs at a plant in the village. Volginsky.

The drugs that will be produced on these lines are included in the list of vital and essential drugs (VEDs), designed to provide medical care in hospitals in such therapeutic areas as anesthesiology and intensive care, oncology, hematology, neurology, cardiology, gastroenterology. These medicines are necessary for hospitals to treat patients with malignant neoplasms, chronic renal failure, liver disease, cardiovascular disease, as well as for medical support of surgical interventions.

Launched lines include ampoule production and a lyophilic plant. The capacity of production areas can reach over 50 million ampoules and vials per year.

As part of the opening of the lines for representatives of the Ministry of Health, the Ministry of Industry and Trade and the Administration of the Vladimir Region, a tour of the plant was held. The guests got acquainted with the modern equipment and technological process in production that meets international standards.

Since the opening of the production complex in Volginsky in 2016, we have been constantly expanding production to supply more high-quality medicines produced in Russia in accordance with international standards. As of October 2019, the plant in Volginsky is a major supplier of oncological drugs in Russia. The launch of additional production of sterile injectable forms is essential to ensure the availability of key medicinal products in hospitals across the country, noted the CEO of Veropharm (Abbott group) Ivan Polyak

2018

Negotiations with the Ministry of Industry and Trade on the signing of the SPIC

The Ministry of Industry and Trade of the Russian Federation has begun negotiations with the pharmaceutical company Abbott Laboratories Veropharm on the signing of a special investment contract (SPIC), the TASS news agency reported on April 10, 2018, citing Alexei Alekhin, director of the department for the development of the pharmaceutical and medical industry of the Ministry of Industry and Trade.

We are discussing the signing of SPICs with Abbott Laboratories, rather with Veropharm. It is too early to talk about the date of signing, this is a negotiation process, - said Alekhine.

According to him, in Belgorod, competencies have been accumulated both in the production of finished dosage forms and in the production of active pharmaceutical substances. The policy of the Ministry of Industry and Trade will be aimed at deepening technological competencies, including in the production of pharmaceutical substances.

We are ready to provide financial support to those manufacturers who are developing something here. For Russian manufacturers, we subsidize part of the costs of conducting clinical trials and organizing the production of substances, - quotes Alekhina TASS.[1]

In general, the plant in Belgorod produces 100 names of drugs for the treatment of cancer, liver diseases, the central nervous system, the gastrointestinal tract, many of which are included in the list of vital drugs. Including localized production of the main drugs Abbott - Dufaston, Dufalac, Duspatalin.

Opening a full-cycle production line for the release of didrogesterone

On April 10, 2018, Abbott announced the opening of a full-cycle production line at the Veropharm plant (part of the Abbott group) in Belgorod. The goal of the launch, as explained in the company, is to localize the production of Abbott to maintain female reproductive health, which meets the strategic tasks of the state to increase the birth rate in Russia.

As you know, didrogesterone ("Dufaston") is widely used in progesterone insufficiency in women to treat infertility, and is also prescribed to preserve pregnancy early. For more than 50 years of use in clinical practice, about 20 million patients around the world took it during pregnancy, Abbott said. The drug, which is included in the list of vital and essential drugs, will now be produced at the Veropharm plant.

The newly opened production line in Belgorod is equipped with high-tech equipment, as well as an autonomous system for obtaining purified water. Production capacity is 200 million tablets per year. The line meets the international GMP quality standard and environmental standards, Abbott said.

Increasing the birth rate has been declared a state task by the country's leadership. This dictates the need to protect the reproductive health of Russian women as one of the priority areas for improving the demographic situation. Today's event makes a significant contribution to the implementation of this important task - to support the reproductive health of women outside and during pregnancy, - said Leila Adamyan, chief obstetrician-gynecologist of the Russian Federation, academician of the Russian Academy of Sciences, Doctor of Medical Sciences, professor, honored scientist of the Russian Federation, deputy director for scientific work of the Federal State Budgetary Institution "Scientific Center of Obstetrics, Gynecology and Perinatology named after Academician V.I..I. Kulakova."

As specified in the company, the introduction of a full-cycle production line was implemented by Abbott as part of a large-scale development program "Veropharm." The program includes the modernization of the company's factories, including their production infrastructure, expansion of research activities, training of employees. The result of the program activities is the compliance of products localized at Veropharm sites with world-class quality standards, Abbott emphasized.

2016

Plan for signing an investment contract with the government of the Belgorod region

In December 2016, it was announced that the government of the Belgorod region and Veropharm were preparing to sign the first special investment contract for the region, which puts the company in strict conditions for the implementation of the project, but guarantees the sale of products in the region, Deputy Governor Oleg Abramov and Veropharm CEO Elena Bushberg told reporters.

A special investment contract assumes that the investor, in return for the support of federal and regional authorities, including to promote products, undertakes a number of obligations to implement the project.

As Mr. Abramov noted, the execution of this contract imposes some restrictions, so not all companies go to its signing. "Veropharm" approached these parameters, and for us to get such a contract is one of the most important tasks, "said the deputy governor.

According to the general director of Veropharm Elena Bushberg, the agreement will allow the company to be guaranteed to sell products in medical institutions in the region.

"A special investment contract of the federal level will be tripartite (the third party is the government of the Russian Federation - ed.) And implies investments in expanding production. We are working on this contract and expect that it will be signed in early 2017. This is important because the stages of reconstruction provide for the opening of new workshops, including the production of hormonal products, and the deep localization of Abbott's products, "said Elena Bushberg

.

In the future, in Belgorod, the pharmaceutical manufacturer intends to open two more new production lines - hormonal drugs and nasal drops.

New workshop of soft and gelatin capsules at the plant in Belgorod

On September 09, 2016, Abbott and its Russian subsidiary Veropharm opened a new production workshop in Belgorod, completing the first stage of a three-year modernization program for the plant with a total investment of 3 billion rubles, Veropharm CEO Elena Bushberg said.

Elena Bushberg emphasized that open production gives up to 55 thousand capsules per hour. The medicine is used in the treatment of strokes.

"More

than 450 thousand strokes are registered in Russia every year. This is a very popular drug for everyone. Before that, we did not make a full cycle of its production here in Belgorod. And this is just the beginning of a big three-year program, "Bushberg concluded

.

The opening of the production of soft gelatin capsules was the first stage in the comprehensive modernization program of the Veropharm plant in Belgorod. The new line is ready to produce drugs for use in neurology.

In addition, within three years, three more new production lines are planned to be opened in Belgorod:

• cytotoxic drugs for use in oncology,
• hormonal drugs and
• two nasal drops.

A special site will also be organized here for the production of one of the key drugs for the entire Abbott business - Dufalaka.

The production of cytotoxic drugs will be launched before the end of 2016, hormonal drugs - in 2017. It also provides for the reconstruction of the microbiological laboratory and the opening of a new research laboratory. The modernization program is scheduled to be completed by the end of 2018, which will double the plant's capacity and fully comply with GMP standards.

At the opening ceremony in Belgorod, Veropharm CEO Elena Bushberg and regional governor Yevgeny Savchenko signed a memorandum of cooperation, which provides for the further development of the plant.

Opening of a plant in the Vladimir region

On September 7, 2016, a new Veropharm plant was opened in the village of Volginsky, Vladimir Region, the construction of which began in 2011. The ceremony was attended by representatives of the Ministry of Industry and Trade, Roszdravnadzor and the Governor of the Vladimir Region Svetlana Orlova.

The Minister of Industry and Trade of the Russian Federation Denis Manturov noted the importance of launching the modern pharmaceutical production of Veropharm in the Vladimir region in the context of the implementation of the Presidential Decrees Russia Vladimir Putin to ensure the production of 90% of vital drugs in Russia by 2018.

"The opening of a new production building is a significant step in the Russian pharmaceutical industry. Now the line of vital oncological and hormonal drugs that were imported from abroad will be produced in Russia, "Denis Manturov emphasized

.

Deputy Minister of Industry and Trade Sergei Tsyb noted that about 1.5 billion rubles were allocated to the Vladimir region as subsidies for the development of the region's pharmaceutical industry.

98.3% of the shares of the Russian company Veropharm at that time belong to the American concern Abbott. The investor invested more than 7 billion rubles in the opening of a new plant. It is equipped with the latest production technologies. The area of ​ ​ the production room was about 19,000 square meters. The Veropharm plant was created in full compliance with international GMP standards and can become a platform for the production of drugs for export.

The plant plans to produce 50 names of drugs, ranging from drugs that help with colds to antitumor drugs that are used in the treatment of oncology, including cancer of the breast, stomach, pancreas, leukemia.

Sergei Tsyb at the opening ceremony presented a license for the production of another Abbott and Veropharm plant in Belgorod, the opening of which should take place in a few days.

2014: Abbott buys Veropharm from banker Roman Avdeev

In December 2014, the American pharmaceutical company Abbott completed the acquisition of the Russian Veropharm. This was reported in the Abbott release. Abbott notes that it is acquiring both the existing Veropharma plants and the production complex currently under construction. In early September 2014, the Foreign Investment Control Commission approved the sale of Veropharm to the American corporation Abbott. The transaction amount amounted to about $650 million.

Abbott gained control of Veropharm by buying back the company's shares for 16.7 billion rubles from Garden Hills banker Roman Avdeev. As previously reported, Avdeev on the eve of the deal brought his stake in Veropharm to 98.3%. Apparently, it was this block of shares that passed to foreign buyers.

Products

Plasters

Veropharm is well known as a manufacturer of patches manufactured at a plant in Voronezh - the first enterprise to organize adhesive plaster production in the USSR in 1944. The plant began production of the legendary bactericidal adhesive plaster with "green" in 1959, a callus plaster - in 1960 and a popular pepper plaster - in 1961. Voronezh Plant became part of Veropharm in 1997. The production capacity of the enterprise as of July 2016 is 470 million medical devices per year.

According to DSM data for 2015, Veropharm occupies about 60% of the medical patch market in Russia.

See: Patch ruler Unilayer"."

Notes